Outset Medical reports FY2025 revenue $119.5M (+5% YoY); provides 2026 guidance $125-130M

Outset Medical, Inc.

2025-FY EPS reported -$5.37 revenue$119,476,000

Q4 revenue $28.9M; full year 2025 revenue $119.5M (+5% YoY); recurring revenue $88.7M (+6%).
Gross margin expanded to 42.4% in Q4 (non-GAAP 42.9%), up ~600 bps vs Q4 2024.
Net loss narrowed to $81.7M in 2025 from $128M in 2024; cash $173M; ops cash burn $46M vs $116M.
Received FDA clearance for next-generation Tablo platform; launch expected in Q2 2026.
FY2026 guidance: revenue $125M-$130M (+5-9% YoY); non-GAAP gross margin low to mid-40%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.